Olafsen
Anja Olafsen, Oslo NO
Patent application number | Description | Published |
---|---|---|
20090304568 | Process for Producing Silane - The invention describes a process for producing silane, wherein magnesium hydride and halosilanes are reacted into silane and a by-product separable into at least two compounds, in a liquid reaction medium at a temperature T≧100° C. and a reaction time/residence time <60 min, and wherein at least one of said compounds is recycled. | 12-10-2009 |
Are Olafsen, Newcastel Upon Tyne GB
Patent application number | Description | Published |
---|---|---|
20100138730 | FAULT DETECTION USING EMBEDDED WATERMARKS - Detection of faults in a transmitted signal stream occurs by recovering, from the information stream, a water mark embedded in the stream prior to transmission. The embedded watermark has data characteristic of stream quality. Thereafter, the at least one watermark property is analyzed to detect faults in the received information stream. | 06-03-2010 |
Kjell Olafsen, Oslo NO
Patent application number | Description | Published |
---|---|---|
20140323752 | METHOD FOR THE MANUFACTURE OF POLYBRANCHED ORGANIC/INORGANIC HYBRID POLYMERS - Polybranched organic/inorganic hybrid polymer and method for its manufacture. The hybrid polymer has the form of an inorganic core carrying organic branches. The core is first prepared by controlled hydrolysis and condensation of a silane with a structure: X—B—Si(—Y) | 10-30-2014 |
20140330034 | METHOD FOR THE MANUFACTURE OF POLYBRANCHED ORGANIC/INORGANIC HYBRID POLYMERS - Polybranched organic/inorganic hybrid polymer and method for its manufacture. The hybrid polymer has the form of an inorganic core carrying organic branches. The core is first prepared by controlled hydrolysis and condensation of a silane with a structure: X—B—Si(—Y) | 11-06-2014 |
Tove Olafsen, Sherman Oaks, CA US
Patent application number | Description | Published |
---|---|---|
20100069616 | ENGINEERED ANTIBODY-NANOPARTICLE CONJUGATES - Conjugates of a C-terminal modified diabody and a nanoparticle are provided in which the C-terminal modification introduces a cysteine residue at a C-terminus of the diabody and the diabody is covalently linked to the nanoparticle via a heterobiofunctional linker attached to the introduced cysteine residue. | 03-18-2010 |
20120283418 | COVALENT DISULFIDE-LINKED DIABODIES AND USES THEREOF - The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions. | 11-08-2012 |
20150044694 | ENGINEERED ANTIBODY-NANOPARTICLE CONJUGATES - Conjugates of a C-terminal modified diabody and a nanoparticle are provided in which the C-terminal modification introduces a cysteine residue at a C-terminus of the diabody and the diabody is covalently linked to the nanoparticle via a heterobiofunctional linker attached to the introduced cysteine residue. | 02-12-2015 |
Tove Olafsen, Reseda, CA US
Patent application number | Description | Published |
---|---|---|
20110268656 | J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE - In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided. | 11-03-2011 |
20120076728 | HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS - This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided. | 03-29-2012 |
20140234215 | J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE - In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided. | 08-21-2014 |
20140271462 | ANTIGEN BINDING CONSTRUCTS TO CD8 - Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein. | 09-18-2014 |